Latest Strategy News

SSH Group Limited reported a 7% revenue decline and a 21% drop in profit after tax for FY2025, while net tangible assets per share doubled amid strategic acquisitions.

333D Ltd has reported a remarkable financial turnaround in FY2025, posting a 426% revenue increase and its first profit after tax, driven by its digital asset management strategy.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

333D Limited has reported a remarkable turnaround for the year ended June 2025, posting a profit after tax of $143,777 on the back of a 426% revenue increase driven by its digital asset management strategy. The company also adopted a Bitcoin Treasury Management Policy, signaling a new phase in its financial approach.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Aeris Resources has delivered a standout FY25 performance, posting a 78% rise in EBITDA and a 286% surge in net profit, driven by strong commodity prices and disciplined cost management.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

RMA Global Ltd reported a 13% revenue increase to $21.1 million in FY25, driven by growth in the US and New Zealand, alongside steady Australian performance. The company also recorded its first full-year positive operating cash flow, marking a significant financial turnaround.

Future Generation Global Limited has reported a 20.8% increase in its investment portfolio over the past year, prompting a boost in its fully franked interim dividend to 4.0 cents per share. This performance outpaces global market averages and underscores the company's sustainable investment approach.

The Agency Group Australia Ltd reported a 12% revenue increase and a return to positive EBITDA in FY2025, driven by record property sales and operational efficiencies, despite a net loss after tax of $5.44 million.